Lyell Immunopharma, Inc. (LYEL) vs Whitehawk Therapeutics Inc (WHWK)

A side-by-side comparison of Lyell Immunopharma, Inc. and Whitehawk Therapeutics Inc across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — LYEL vs WHWK

growth of $100 · dividends reinvested · last 5y
LYEL -97.3% (-51.5%/yr)WHWK -86.7% (-33.2%/yr)WHWK compounded faster over this window
050100Start $10020222023202420252026$3$13
LYEL WHWK

LYEL vs WHWK: by the numbers

  • •LYEL is the larger company ($211M vs $206M market cap).
  • •Both run net losses; WHWK's is the smaller (-288.26% vs -920285.19% net margin).

Metrics side by side

Valuation

MetricLYELWHWK
P/S ratio7814.17N/A
P/B ratio0.901.13

Profitability

MetricLYELWHWK
Gross margin-31952.78%89.36%
Operating margin-566038.89%-1601.12%
Net margin-920285.19%-288.26%
ROE-106.27%-43.64%
ROIC-70.80%-47.05%

Growth (annualized)

MetricLYELWHWK
Revenue CAGR (5Y)-68.32%N/A
Total return CAGR (5Y)-48.18%-33.13%

Frequently asked

How have LYEL and WHWK total returns compared?
Over the past 5 years, LYEL delivered -48.18% and WHWK delivered -33.13% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.